Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study for Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

 Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study for Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study for Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

Shots:

  • The P-III ALTA-1L study involves assessing of Alunbrig (180mg, qd for 7days lead in 90mg qd) vs Crizotinib (250mg, bid) in 275 patients with anaplastic lymphoma kinase-positive (ALK+) LA/ metastatic NSCLC, prior not treated with an ALK inhibitor
  • Following 2yrs. follow up, 76% & 57% reduction in disease progression in newly diagnosed & in all patients. Additionally, mPFS in patients with brain metastases (not reached vs 5.6mos.); intracranial ORR (78% vs 26%); intracranial DOR (not reached vs 9.2mos.), efficacy with follow up of 25mos., mPFS (29.4 vs 9.2mos.); ORR (74% vs 62%); mDOR (not reached vs 13.8mos.)
  • Alunbrig is a potent and selective TKI inhibitor, designed to target and inhibit ALK fusion protein in NSCLC and has received the US FDA’s accelerated approval in Apr’2017

Click here to­ read full press release/ article | Ref: Takeda  | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post